Manage the
business of science.

Manage the
business of science.

Manage the
business of science.

Orchestra helps R&D organizations reduce the operational complexity of drug development

Q2 2025 board meeting

Base case

Sources

Tables

Charts

Base case

cash out

Feb 2026

Sep 2026

total burn

$30,247,923

$26,963,436

average monthly burn

$772,219

$691,370

ending cash

$17,482,592

$14,509,558

H1 2025

H2 2025

H1 2026

H2 2026

H1 2027

H2 2027

Antibody program 001

Lead ID

🎯

DC Selection

🥇

Stable pools

🧬

Go for GLP Tox

🐭

Go for GMP

🏭

IND

🏛️

Go to Phase 1

💉

Antibody program 004

Phase 1 Acceleration

Go for GMP

🏭

Comparability done

🐭

IND

🏛️

-3 months

Go to Phase 1

💉

-3 months

End of Phase 1

🏥

-3 months

Finances

$25M

$20M

$15M

$10M

Last actual

Cash out

Base case: Projected cash balance

Base scenario: Cumulative spend

TODAY

Q2 2025 board meeting

Base case

Sources

Tables

Charts

Base case

cash out

Feb 2026

Sep 2026

total burn

$30,247,923

$26,963,436

average monthly burn

$772,219

$691,370

ending cash

$17,482,592

$14,509,558

H1 2025

H2 2025

H1 2026

H2 2026

H1 2027

H2 2027

Antibody program 001

Lead ID

🎯

DC Selection

🥇

Stable pools

🧬

Go for GLP Tox

🐭

Go for GMP

🏭

IND

🏛️

Go to Phase 1

💉

Antibody program 004

Phase 1 Acceleration

Go for GMP

🏭

Comparability done

🐭

IND

🏛️

-3 months

Go to Phase 1

💉

-3 months

End of Phase 1

🏥

-3 months

Finances

$25M

$20M

$15M

$10M

Last actual

Cash out

Base case: Projected cash balance

Base scenario: Cumulative spend

TODAY

Q2 2025 board meeting

Base case

Sources

Tables

Charts

Base case

cash out

Feb 2026

Sep 2026

total burn

$30,247,923

$26,963,436

average monthly burn

$772,219

$691,370

ending cash

$17,482,592

$14,509,558

H1 2025

H2 2025

H1 2026

H2 2026

H1 2027

H2 2027

Antibody program 001

Lead ID

🎯

DC Selection

🥇

Stable pools

🧬

Go for GLP Tox

🐭

Go for GMP

🏭

IND

🏛️

Go to Phase 1

💉

Antibody program 004

Phase 1 Acceleration

Go for GMP

🏭

Comparability done

🐭

IND

🏛️

-3 months

Go to Phase 1

💉

-3 months

End of Phase 1

🏥

-3 months

Finances

$25M

$20M

$15M

$10M

Last actual

Cash out

Base case: Projected cash balance

Base scenario: Cumulative spend

TODAY

Align your organization from bench to boardroom

R&D Planning

Build a centralized roadmap across leadership, programs, and scientific groups

Financial Modelling

01

Unified Planning

02

intelligent operations

03

Decision Support

01

Unified Planning

Align your organization from bench to boardroom
R&D Planning

Build a centralized roadmap across leadership, programs, and scientific groups

Financial Modelling

Forecast and analyze spend across R&D, operations, and personnel

02

intelligent operations

Automatically track progress, risks, and outcomes
AI-Powered Progress & Risk Tracking

Get to ground truth by interpreting meetings, documents, and reports

R&D Operations

Track execution against the plan in a single view

03

Decision Support

Plans change. 
Plan for that too.
Scenario modelling

Assess scenarios combinatorially across programs and budgets

AI-powered knowledge base

Leverage institutional knowledge to drive decisions.

01

Unified Planning

Align your organization from bench to boardroom

R&D Planning

Build a centralized roadmap across leadership, programs, and scientific groups

Financial Modelling

Forecast and analyze spend across R&D, operations, and personnel

02

intelligent operations

Automatically track progress, risks, and outcomes

AI-Powered Progress & Risk Tracking

Get to ground truth by interpreting meetings, documents, and reports

R&D Operations

Track execution against the plan in a single view

03

Decision Support

Plans change. 
Plan for that too.

Scenario modelling

Assess scenarios combinatorially across programs and budgets

AI-powered knowledge base

Leverage institutional knowledge to drive decisions

The intelligent management system for life sciences R&D